{"id":"W4385256763","doi":"10.1016/j.eururo.2023.06.006","title":"Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study","year":2023,"lang":"en","type":"article","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"Merck Sharp and Dohme","keywords":"Medicine; Axitinib; Sunitinib; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Kidney cancer; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003076694,0.0004656989,0.0009150214,0.0002613162,0.0001481046,0.00000739549,0.0003560164,0.00008180149,0.0002161443],"category_scores_gemma":[0.0002137161,0.0003239897,0.0004339028,0.0005733328,0.0002620008,0.00004058047,0.0002331214,0.0002248421,0.0002646832],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002209633,"about_ca_system_score_gemma":0.0002405554,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002268975,"about_ca_topic_score_gemma":0.0001362845,"domain_scores_codex":[0.9967071,0.0007355892,0.0008252994,0.0006588068,0.0004859207,0.0005872159],"domain_scores_gemma":[0.9973627,0.0004928121,0.000444681,0.001280772,0.0001976453,0.0002213975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5078872,0.05775109,0.09191787,0.001249952,0.005994751,0.05058474,0.07281185,0.01146844,0.1167765,0.0005600887,0.007445727,0.07555175],"study_design_scores_gemma":[0.3842606,0.1981404,0.3087885,0.00005970799,0.003804729,0.0003113974,0.003072955,0.0004831302,0.07708897,0.00003330283,0.02322876,0.0007276182],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679524,0.0005744005,0.000004306855,0.0004756309,0.0007723806,0.001702434,0.00009493897,0.0001077186,0.02831578],"genre_scores_gemma":[0.9947273,0.0000822882,0.00003339834,0.00007402389,0.0002168083,0.00005903195,0.0001785405,0.0001153172,0.004513361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2168706,"threshold_uncertainty_score":0.9999212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05018944831186409,"score_gpt":0.3036993253931792,"score_spread":0.2535098770813151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}